Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.

Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.

Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the third leading cause of cancer death worldwide. The only approved systemic treatment for unresectable HCC is the oral kinase inhibitor, sorafenib. Recombinant human acid sphingomyelinase (rhASM), which hydrolyzes sphingomy...

Full description

Bibliographic Details
Main Authors: Radoslav Savić, Xingxuan He, Isabel Fiel, Edward H Schuchman
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3665770?pdf=render

Similar Items

Similar Items